-+ 0.00%
-+ 0.00%
-+ 0.00%
Bactiguard Q2 FY26 adjusted EBITDA rises 27.27% to SEK 5.6 million; revenue increases 9.6% to SEK 57.1 million
Share
Listen to the news
Bactiguard Q2 FY26 adjusted EBITDA rises 27.27% to SEK 5.6 million; revenue increases 9.6% to SEK 57.1 million
  • Bactiguard Q2 2026 revenue rose 9.6% to SEK 57.1 million; adjusted EBITDA increased to SEK 5.6 million from SEK 4.4 million.
  • Net loss widened slightly to SEK 8.2 million; cash flow from operating activities improved to SEK 12.4 million from SEK 1.7 million.
  • Net sales climbed 16% excluding currency; Wound Management revenue jumped 67% to SEK 22 million, led by Hydrocyn aqua growth.
  • BD revenue rose to SEK 28.2 million; a new long-term agreement restated and deepened the 35-year partnership.
  • Zimmer Biomet revenue was SEK 3.8 million; Bactiguard cited growing coated-implant use in trauma patients and double-digit product sales growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bactiguard Holding AB published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending